1. Home
  2. Live Updates
  3. Lenalidomide

Live Breaking News & Updates on Lenalidomide

Stay informed with the latest breaking news from Lenalidomide on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Lenalidomide and stay connected to the pulse of your community

Pharmac proposes to fund new blood cancer multiple myeloma drug pomalidomide

Multiple myeloma, a common blood cancer , is incurable, but can be survived for years with the right treatment and medicines, which have greatly improved....

New-zealand , New-zealanders , Tim-edmonds , David-hughes , Simon-clark , Lenalidomide-viatris , Nichola-oakenfull , Blood-cancer-new-zealand , Pharmac , Proposes , To

Heterogeneous Practices Common in Treatment, Monitoring of Patients With Myelodysplastic Syndrome With Del(5q)

This study builds on previous evidence for lenalidomide-induced selective advantage for TP53-mutant clones.

Blood-cancer , Image-credit , Myelodysplastic-syndrome- , Mds-with-del-5q- , Lenalidomide , Mds-del-5q- ,

First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia

Amy DeZern, MD, MHS, provides clinical insights on the first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Amy-dezern , Evolving-treatment-landscape , Myelodysplastic-syndromes , Line-treatment , Mds , First-line-treatment , First-line-therapies , Anemia , Symptomatic-anemia , Mds-treatment , Myelodysplastic-syndromes-treatment

ASH 2023: Analyzing IsKia Trial

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

Conference-perspectives , Multiple-myeloma , Analyzing-iskia , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib

Examining Data from MonumenTAL-2 Study

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

Conference-perspectives , Multiple-myeloma , American-society-of-hematology , Ash , Newly-diagnosed-multiple-myeloma , Triplet-therapy , Quadruplet-therapy , Perseus-trial , Daratumumab , Bortezomib , Lenalidomide

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.

United-states , California , San-diego , Australia , America , Lorenzo-falchi , Drug-administration , Eastern-cooperative-oncology-group , Subcutaneous-epcoritamab-with-rituximab , Patients-with-relapsed , Refractory-follicular , Partnership-with

The Evolving Treatment Paradigm for Transplant Ineligible MM

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Multiple-myeloma , Evolving-treatment-paradigm , Transplant-ineligible , Mm , Newly-diagnosed-multiple-myeloma , Ndmm , Mm-treatment , Transplant-eligible , Daratumumab , Lenalidomide , Dexamethasone

Additional Analyses Needed to Optimize Treatment Efficacy, Sequencing in MM

This literature review investigated outcomes related to relapsed/refractory multiple myeloma (MM) among patients 65 years and older.


Cochrane-collaboration , Mat-hayward , Relapsed-refractory-multiple-myeloma , Daratumumab , Lenalidomide , Dexamethasone- ,

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Bispecifict-cell-engager , Beyond-therapy , Fl , Third-line , Bispecific , Odronextamab , Epcoritamab , Mosunetuzumab

Zanubrutinib as Third-Line and Beyond Therapy for FL

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Laurie-sehn , Recent-updates , Follicular-lymphoma , Mantle-cell-lymphoma , Beyond-therapy , Fl , Zanubrutinib , Third-line-therapy , Third-line-and-beyond , Obinutuzumab , Durable-response